MB Therapeutics awarded France 2030 project grant: accelerating innovation in healthcare
MB Therapeutics has been selected as a laureate of the France 2030 call for projects, a national strategic program designed to support breakthrough innovations in priority sectors, including healthcare innovation. This recognition comes with significant financial support that will accelerate the development of our next-generation medicine and strengthen our industrial growth in France and internationally.
Strategic support to accelerate the development of next-generation medicine
This funding is part of the France 2030 initiative, which aims to support high-impact, high-value healthcare innovations that contribute to France’s health sovereignty. For MB Therapeutics, this national recognition represents a decisive accelerator in the development of our next-generation medicine, built on a bold and forward-looking approach.
With this support, we will:
- Strengthen our R&D program, scaling up our scientific innovation capabilities.
- Industrialize our therapeutic solutions, with robust, production-ready processes suited for clinical and commercial deployment.
- Structure our long-term growth, by consolidating our business model and expansion strategy in France and abroad.
France 2030: a powerful driver for transforming the healthcare sector in France
The France 2030 program, led by the French government and implemented at the regional level, aims to foster breakthrough technologies in strategic sectors. As part of this initiative, MB Therapeutics has been selected as a regional laureate of the “Innovation Projects” call, a strong recognition of the relevance and territorial anchoring of our technological approach.
We have been awarded €500,000 in public funding to accelerate our R&D program, support the industrialization of our therapeutic inks, and structure our production site in Montpellier. This support builds on the momentum of our recent €2 million fundraising round, and marks a key milestone toward our mission: making localized, safe, and personalized medicine production accessible directly within pharmacies.
Recognition of our vision and commitment to innovation
This funding represents a major acknowledgment of the quality of our research, the relevance of our model, and the daily commitment of our teams to delivering concrete solutions to public health challenges.
Being supported under the France 2030 initiative is a mark of credibility that validates our scientific and strategic choices, and gives us the means to move faster and further in fulfilling MB Therapeutics’mission.
